AAPS PharmSci 360 2024: The Future of Bioanalysis

As part of its AAPS PharmSci 360 2024 coverage, Pharmaceutical Technology^® sat down with Xiao-Yan Cai, PhD, co-founder and CEO of Accurant Biotech, to discuss trends in bioanalysis and conversations about the direction the approach is going, both internally at Accurant and with colleagues and competitors at events like AAPS.

Cai talked about the collaborative efforts the industry must take to understand each other’s particular fields of expertise and use that knowledge to further their own research.

“Everybody is passionate about their platform, per se. I see perhaps a bigger good for everyone always. So, if it's necessary to use LC–MS [liquid chromatography—mass spectrometry], that is just better, for example,” Cai said. “Perfect example is insulin, right? Insulin is an important medicine for diabetes, and the insulin is a kind of like peptide-ish—okay, smaller, and you want to differentiate ... fast-acting, long-acting, different insulin analogues. The large-molecule platforms are just inferior compared to LC–MS. You know, even though I'm totally on this side, I'm on the biologic side, I'm usually [working with] immunoassay platforms, PCR, cell-based assays, anything biologics, right? But I'm very scientific driven. Whatever can solve the problem.”

Click the above video to watch the full interview.

Visit Accurant Biotech at Booth 1725. AAPS PharmSci 360 is being held from Oct. 20–23, 2024 in Salt Lake City, Utah.